Has apotex disclosed its ruxolitinib's fda filing intentions?

What Apotex has said about its ruxolitinib filing
Apotex has not released any public statement indicating a plan to file a new drug application for ruxolitinib with the FDA.

Could the company file soon?
If Apotex decides to move forward, the timing would depend on regulatory strategy, patent status, and competitive dynamics. No public timeline has been announced.

Who else is pursuing FDA approval for ruxolitinib?
Other manufacturers have applied or are planning applications, but Apotex has not joined that group in any disclosed filing.

What does the patent picture look like?
The existing patents for ruxolitinib could shape when and whether Apotex might file, but the company has not revealed its strategy in this regard.

What information might Apotex release next?
A formal filing announcement would likely appear on the company’s investor relations page, a press release, or a regulatory filing database. No such notice has been published to date.